News | 25 February 2013
PBR Staff Writer Published 25 February 2013. The US Food and Drug Administration (FDA) has approved Lupin Pharmaceuticals' new drug application (NDA) for SUPRAX (Cefixime) for Oral Suspension, 500 mg/5mL. The new dosage strength is indicated for ...
Click on the link to read the full article at Pharmaceutical Business Review
(This link will open in a new window)